Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 7/20 | 0.67 |
| ▸ | MAOA | P21397 | 6/20 | 0.66 |
| ▸ | MAOB | P27338 | 6/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SDHA | P31040 | 1/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222787 | 1.00 | CALML3 (0.67) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| SCHEMBL1222791 | 1.00 | CALML3 (0.67) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| SCHEMBL1223712 | 0.90 | CALML3 (0.55) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL1223711 | 0.90 | CALML3 (0.55) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL3323279 | 0.88 | CALML3 (0.80) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| SCHEMBL1222864 | 0.88 | CALML3 (0.52) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL1222866 | 0.88 | CALML3 (0.52) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL3323285 | 0.88 | CALML3 (0.80) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| SCHEMBL3323276 | 0.88 | CALML3 (0.80) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| SCHEMBL19938071 | 0.87 | CALML3 (0.64) | CALML3MAOAMAOBCYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| WO-2014174522-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2014-10-30 | — | — | WO | disclosed |
| EP-2296651-B1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES FOR TREATING BACTERIAL INTESTINAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-07-18 | — | — | EP | disclosed |
| US-8124772-B2 | Intermediate products for producing oxazolidinone-quinolone hybrids | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2012-02-28 | — | — | US | disclosed |
| US-20090306389-A1 | Intermediate products for producing oxazolidinone-quinolone hybrids | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2009-12-10 | — | — | US | disclosed |
| US-7557214-B2 | Intermediate products for producing oxazolidinone-quinolone hybrids | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2009-07-07 | — | — | US | disclosed |
| US-20070004769-A1 | Intermediate products for producing oxazolidinone-quinolone hybrids | MORPHOCHEM AKTIEGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306389-A1 | Intermediate products for producing oxazolidinone-quinolone hybrids | OXA1L, NQO1, NQO2 | CALML3 4334/4885MAOA 590/4885MAOB 391/4885 |
| US-20070004769-A1 | Intermediate products for producing oxazolidinone-quinolone hybrids | OXA1L, NQO1, NQO2 | CALML3 4334/4885MAOA 590/4885MAOB 391/4885 |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | CCNO, PTGDR, CCNE1 | CALML3 4273/4885MAOA 2199/4885MAOB 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.